#4329
Multivariate survival analyses of 544 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC) given first-line chemotherapy (NORDIC NEC 2)
Introduction:
Digestive high-grade neuroendocrine neoplasms (HG-NEN) are rare and consist of neuroendocrine tumours G3 (NET G3) and neuroendocrine carcinomas (NEC). They differ in clinical and molecular characteristics, response to treatment and prognosis. Limited prospective data are available on prognostic factors for survival in patients given first-line chemotherapy outside of clinical trials.
Conference:
Presenting Author:
Authors:
Sorbye H,
Hjortland G,
Vestermark L,
Ladekarl M,
Svensson J,
Keywords:
neuroendocrine neoplasm,
neuroendocrine carcinoma,
digestive,
high-grade,
neuroendocrine tumour grade 3,
#2109
Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)
Introduction:
High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin +etoposide) is considered standard first-line palliative treatment. Etoposide is frequently administered intravenously, however oral etoposide is often used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- & intrapatient variability and patient compliance.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Ali A
Authors:
Ali A,
Grönberg M,
Hjortland G,
Grønbæk H,
Ladekarl M,
Keywords:
chemotherapy,
Neuroendocrine Neoplasms,
Intravenous,
Oral,
survival,
#1455
Expression of Mutated p53 Protein in Gastroenteropancreatic Neuroendocrine Carcinoma (WHO G3)
Introduction:
Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, highly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short-lasting.
Conference:
13th Annual ENETSConcerence (2016)
Presenting Author:
Authors:
Ali A,
Grönberg M,
Federspiel B,
Hjortland G,
Ladekarl M,
Keywords:
Neuroendocrine Carcinoma,
mutation,
p53,
overall survival,
